Almac Group opens additional companion diagnostic laboratory in Durham, NC, US
The facility will provide a US base to support increased demand for Almac's CDx development partnerships
Almac Group’s Diagnostics Business Unit has opened a new companion diagnostic development facility in the Research Triangle Park region of North Carolina, US.
The facility will provide a US base to support increased demand for Almac's CDx development partnerships as well as a Clinical Laboratory Improvement Amendments (CLIA)-accredited laboratory to support the downstream delivery of assays for patient testing.
Along with headquarters in Europe and partnerships in Asia, the new facility in the US will provide Almac Diagnostics with a strong global presence to continue to meet increasing customer demand and to support a growing client base.
The state-of-the-art laboratory is equipped with microarray and qPCR platforms appropriate for companion diagnostic development and will operate both research-use-only and clinical diagnostic tests. Plans are also in place to add additional technology platforms including next-generation sequencing (NGS) in the coming year.
‘The opening of our new CDx facility in the US is Almac Diagnostics’ latest initiative to better serve our global biopharma partners. As we experience increased client demand for our companion diagnostic development services, this latest expansion will significantly enhance Almac’s offering, increasing capacity and further demonstrating our commitment to personalised healthcare,’ said Professor Paul Harkin, President and Managing Director of Almac Diagnostics.
